











Enhancer connectome in primary human cells identifies target genes of disease-associated DNA elements

Maxwell R Mumbach^{1,2,12}, Ansuman T Satpathy^{1,3,12} , Evan A Boyle^{1,2,12} , Chao Dai^{1,12}, Benjamin G Gowen^{4,5} , Seung Woo Cho¹, Michelle L Nguyen⁶, Adam J Rubin⁷, Jeffrey M Granja^{1,2}, Katelynn R Kazane^{4,5}, Yuning Wei¹, Trieu Nguyen⁸, Peyton G Greenside², M Ryan Corces¹, Josh Tycko² , Dimitre R Simeonov^{6,9} , Nabeela Suliman², Rui Li¹, Jin Xu¹, Ryan A Flynn¹, Anshul Kundaje² , Paul A Khavari⁷ , Alexander Marson^{5,6,10}, Jacob E Corn^{4,5} , Thomas Quertermous⁸, William J Greenleaf^{1,2,10,11,13}  & Howard Y Chang^{1,7,13} 

The challenge of linking intergenic mutations to target genes has limited molecular understanding of human diseases. Here we show that H3K27ac HiChIP generates high-resolution contact maps of active enhancers and target genes in rare primary human T cell subtypes and coronary artery smooth muscle cells. Differentiation of naive T cells into T helper 17 cells or regulatory T cells creates subtype-specific enhancer–promoter interactions, specifically at regions of shared DNA accessibility. These data provide a principled means of assigning molecular functions to autoimmune and cardiovascular disease risk variants, linking hundreds of noncoding variants to putative gene targets. Target genes identified with HiChIP are further supported by CRISPR interference and activation at linked enhancers, by the presence of expression quantitative trait loci, and by allele-specific enhancer loops in patient-derived primary cells. The majority of disease-associated enhancers contact genes beyond the nearest gene in the linear genome, leading to a fourfold increase in the number of potential target genes for autoimmune and cardiovascular diseases.

Gene expression programs are intimately linked to the hierarchical organization of the genome. In mammalian cells, each chromosome is organized into hundreds of megabase-sized topologically associated domains (TADs), which are conserved from early stem cells to differentiated cell types¹. Within this invariant TAD scaffold, cell-type-specific enhancer–promoter interactions establish regulatory gene expression programs². Standard methods require tens of millions of cells to obtain high-resolution interaction maps and confidently assign enhancer–promoter contacts^{3–5}. Thus, the principles that govern enhancer–promoter conformation in disease-relevant patient samples are incompletely understood. This gap in understanding is particularly problematic for interpreting the molecular functions of inherited risk factors for common human diseases, which reside in intergenic enhancers or other noncoding DNA features in up to 90% of cases^{6–9}. Such disease-relevant enhancers may not influence the expression of the nearest gene (often reported as the default target in the literature) and may instead act in a cell-type-specific manner on distant target genes residing up to hundreds of kilobases away^{2,10–14}. Recently, systematic perturbations of regulatory elements in select gene loci have shown that the effects of individual regulatory elements

on gene activity can be predicted from the combination of (i) enhancer activity (marked by histone H3 lysine 27 acetylation (H3K27ac) level) and (ii) enhancer–target looping^{5,15}. Here we leverage this insight to capture the combination of these two types of information across the genome in a single assay, mapping the enhancer connectome in disease-relevant primary human cells.

RESULTS

H3K27ac HiChIP identifies functional enhancer interactions

We recently developed HiChIP, a method for sensitive and efficient analysis of protein-centric chromosome conformation¹⁶. Cohesin HiChIP in GM12878 cells identified similar numbers of loops as *in situ* Hi-C (~10,000) with high correlation ($R = 0.83$), demonstrating that HiChIP captures loops with high sensitivity and specificity. Here we evaluated the enhancer- and promoter-associated mark H3K27ac^{17–19} as a candidate factor to selectively interrogate enhancer–promoter interactions across the genome. We performed H3K27ac HiChIP in mouse embryonic stem (ES) cells to compare to cohesin HiChIP (**Supplementary Fig. 1a** and **Supplementary Table 1**)¹⁶. 3,552 of the 4,191 H3K27ac HiChIP loops in mouse ES

¹Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, California, USA. ²Department of Genetics, Stanford University School of Medicine, Stanford, California, USA. ³Department of Pathology, Stanford University School of Medicine, Stanford, California, USA. ⁴Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, California, USA. ⁵Innovative Genomics Institute, University of California, Berkeley, Berkeley, California, USA. ⁶Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, California, USA. ⁷Program in Epithelial Biology, Stanford University School of Medicine, Stanford, California, USA. ⁸Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA. ⁹Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, California, USA. ¹⁰Chan Zuckerberg Biohub, San Francisco, California, USA. ¹¹Department of Applied Physics, Stanford University, Stanford, California, USA. ¹²These authors contributed equally to this work. ¹³These authors jointly directed this work. Correspondence should be addressed to H.Y.C. (howchang@stanford.edu) or W.J.G. (wjg@stanford.edu).

Received 27 March; accepted 1 September; published online 25 September 2017; doi:10.1038/ng.3963

cells were also identified by cohesin HiChIP. The H3K27ac-biased loops (\log_2 (fold change) > 1) spanned shorter distances than the cohesin-biased loops and were enriched for H3K27ac ChIP-seq peaks (78.9%; **Supplementary Fig. 1b–f** and **Supplementary Table 2**). Moreover, systematic titration of input material showed that H3K27ac HiChIP retained high signal fidelity and reproducibility when using from 25 million to 50,000 cells as input material (loop signal correlation $r = 0.918$; **Supplementary Figs. 2** and **3**). Therefore, H3K27ac HiChIP identifies high-confidence chromatin loops focused around enhancer interactions from limited cell numbers.

To capture (i) conformational change during T cell differentiation and (ii) cell-type-specific chromatin contacts of risk variants for autoimmune diseases in protective and pathogenic T cell types, we performed H3K27ac HiChIP on primary human naive T cells ($CD4^+CD45RA^+CD25^-CD127^{hi}$), regulatory T (T_{reg}) cells ($CD4^+CD25^+CD127^{lo}$), and T helper 17 (T_H17) cells ($CD4^+CD45RA^-CD25^-CD127^{hi}CCR6^+CXCR5^-$) directly isolated from donors (**Fig. 1a,b** and **Supplementary Fig. 4a**)^{20,21}. T_H17 cells were sorted to include autoimmune disease-relevant pathogenic T_H17 cells and to exclude follicular helper T cells with a distinct surface phenotype and immune function (**Supplementary Fig. 4a**)^{22–24}. Peripheral blood $CD4^+$ T cells were obtained from three healthy subjects, isolated by FACS, and subjected to H3K27ac HiChIP. The HiChIP libraries from each subset were high quality; greater than 40% of the reads represented unique paired-end tags (PETs) (**Supplementary Fig. 4b–d** and **Supplementary Table 1**). Furthermore, the libraries exhibited high 1D signal enrichment at enhancers and promoters and globally recapitulated publically available H3K27ac ChIP-seq data sets (74.7% overlap of ChIP-seq and 1D HiChIP peaks; **Fig. 1c**)²⁵. Inspection of the interaction matrix at progressively higher resolution showed chromatin compartments, TADs, and focal loops, as previously reported in high-resolution Hi-C and HiChIP analyses from cell lines (**Fig. 1b**)^{4,16}. Notably, H3K27ac HiChIP maps were capable of identifying focal interactions at 1-kb resolution, which is comparable to the resolution for *in situ* Hi-C maps generated from 100-fold more cells and sequenced to 13-fold greater depth⁴ (**Fig. 1b**).

Previous saturation perturbation screens demonstrated that functional enhancers can be identified by integrating H3K27ac ChIP-seq signal with chromosome conformation contact strength (Hi-C)⁵. Because H3K27ac HiChIP combines these two components into one assay, we reasoned that HiChIP signal, which we term enhancer interaction signal (EIS), should identify functional regulatory elements. To validate this prediction, we first generated H3K27ac HiChIP maps in a chronic myelogenous leukemia cell line (K562) as a direct comparison to published high-resolution CRISPR interference (CRISPRi) screens⁵. We then examined the 3D enhancer landscape of the *MYC* and *GATA1* loci using virtual 4C (v4C) analysis, where a specific genomic position is set as an anchor viewpoint and all interactions occurring with that anchor are visualized in 2D¹⁶. v4C analysis of the *MYC* promoter demonstrated that EIS in K562 cells captured all functional enhancers identified in the CRISPRi screen (**Fig. 2a**). Analysis of the *GATA1* locus demonstrated a similar agreement between the two methods (**Fig. 2b**). Quantitatively, the EIS in K562 cells was significantly correlated with CRISPRi score in the same cell type, whereas the EIS in GM12878 (GM; B cell lymphoblast) cells was not correlated with the K562 CRISPRi score (Spearman's $\rho = 0.332$ and 0.145 ; $P = 9.25 \times 10^{-5}$ and 0.1246 ; **Fig. 2c**).

We found the enhancer landscapes of the *MYC* promoter to be highly cell type specific. v4C analysis of the *MYC* promoter in GM and My-La ($CD4^+$ T cell leukemia) cells showed dramatically different regulatory interactions with the promoter as compared to K562 cells (**Fig. 2d**).

To validate EIS specificity, we performed CRISPRi experiments in GM cells using single guide RNAs (sgRNAs) targeting enhancers identified in either GM or My-La HiChIP maps, as well as a positive-control sgRNA targeting the *MYC* promoter and a negative-control sgRNA targeting lambda phage sequence (**Fig. 2e**). As expected, we found that simultaneous CRISPRi perturbation of GM enhancers, but not My-La enhancers, impacted *MYC* expression and cell growth in GM cells (**Fig. 2e**).

Finally, we focused on the *CD69* locus, where a high-resolution CRISPR activation (CRISPRa) screen identified three enhancers upstream of the transcription start site (TSS)²⁶. These sites were also identified by H3K27ac HiChIP in naive T cells. Moreover, HiChIP identified four additional distal enhancers that were outside the region spanned by the sgRNA tiling array (**Fig. 2f** and **Supplementary Fig. 5**). To functionally validate these new enhancers, we performed CRISPRa experiments in Jurkat cells with sgRNAs targeting these enhancers, the *CD69* promoter, and the *KLRF2* promoter as a locus negative control, as well as a non-human-genome-targeting negative control. We observed a significant increase in *CD69* RNA and protein levels in the four HiChIP enhancers as compared to the negative controls (**Fig. 2g** and **Supplementary Fig. 5**). Interestingly, two of the four new enhancers identified were within the promoter regions of distant genes. These findings are in line with previous reports that identified widespread distal gene regulatory functions of promoters across the genome^{27,28}. Altogether, these results suggest that H3K27ac HiChIP EIS identifies functional regulatory elements and that enhancers that regulate a gene of interest can differ significantly between cell types.

Landscape of enhancer interactions in primary T cells

We examined global features of the enhancer connectome associated with cellular differentiation from naive T cells into either T_H17 cells or T_{reg} cells. We identified a total of 10,706 high-confidence loops in the union set of the three cell types (**Supplementary Table 2**). Analysis of loop read support between biological replicates demonstrated high reproducibility (**Supplementary Fig. 4c**), and ~91% of loop anchors were associated with either a promoter or an enhancer²⁹, as expected, with a median distance of 130 kb (**Supplementary Fig. 6a,b**). Notably, high-resolution enhancer-promoter connectivity maps identified several features that could not be discerned from 1D epigenomic data (that is, H3K27ac ChIP-seq or assay for transposase-accessible chromatin using sequencing, ATAC-seq; **Fig. 3a**). These features included (i) 'enhancer skipping': enhancers that had stronger EIS with a more distal target promoter; (ii) higher-order structures such as 'enhancer cliques' (related to loop cliques³⁰): multiple regulatory elements that had strong EIS with a single target promoter; (iii) promoter-promoter interactions^{13,31}; and (iv) 'enhancer switching': enhancers that exhibited differential EIS with a target promoter in a cell-type-specific manner (**Fig. 3a**).

We found that EIS contacts were very cell type specific. After quantile-quantile normalization of contact reads at high-confidence loops (correcting for false positives caused by 1D fragment visibility; **Supplementary Note**), we focused on the top and bottom 5% of EIS ranked by cell type bias for each pairwise comparison (**Supplementary Figs. 6c–g** and **7**, and **Supplementary Tables 3** and **4**). Cell-type-specific enhancer loop anchors identified genes encoding canonical T cell subtype transcription factors and effector molecules (**Fig. 3b** and **Supplementary Figs. 8** and **9**). Deeper v4C analysis of shared and cell-type-specific loci pinpointed regulatory elements interacting with each gene promoter of interest as well as local conformational landscape changes (**Supplementary Figs. 8** and **9**). Transcription factor motifs located within cell-type-specific loop anchors were enriched for transcription factors known to drive T cell subtype differentiation and nominated new transcription




Figure 1 HiChIP identifies high-resolution chromosome conformation in primary human T cells. (a) Primary T cell H3K27ac HiChIP experimental outline. (b) Left, FACS strategy for naive, T_{H17} , and T_{reg} cells from total peripheral blood $CD4^+$ T cells. Number represents the percentage of total $CD4^+$ T cells within that gate. Right, Knight–Ruiz (KR) matrix-balanced interaction maps for naive, T_{H17} , and T_{reg} cells at 500-kb, 25-kb, and 5-kb resolution, and raw interaction maps at 1-kb resolution, centered on the *KLF2*, *RBPJ*, and *LRRC32* loci. (c) HiChIP 1D and 3D signal enrichment at the *RORC* locus in T_{H17} over naive T cells.

factors involved in regulation (Fig. 3c). Furthermore, cell type EIS bias was associated with differential expression of genes located within corresponding EIS anchors for the same cell type (naive to T_{H17} : Spearman's $\rho = 0.242$ and $P = 4 \times 10^{-15}$; naive to T_{reg} : Spearman's $\rho = 0.207$ and $P = 2 \times 10^{-11}$); Fig. 3d).

Cell-type-specific EIS may be driven by cell-type-specific enhancer activation (based on H3K27ac ChIP-seq) or stable enhancer activation with cell-type-specific looping (Hi-C) in a gene-specific manner. We first examined H3K27ac ChIP-seq signal at differential EIS anchors and found that many biased H3K27ac HiChIP interactions




Figure 2 Validation of regulatory elements identified by H3K27ac HiChIP with CRISPR interference and activation. **(a)** Interaction profile of the *MYC* promoter in K562 H3K27ac HiChIP at 10-kb resolution. K562 H3K27ac ChIP-seq data are from the Encyclopedia of DNA Elements (ENCODE). CRISPRi-validated regulatory regions in K562 cells are indicated⁵. **(b)** Interaction profile of the *GATA1* promoter in K562 H3K27ac HiChIP at 1-kb resolution. CRISPRi-validated regulatory regions in K562 cells are indicated⁵. **(c)** Correlation of *MYC* K562 H3K27ac HiChIP signal with maximum CRISPRi score within the HiChIP 10-kb window. **(d)** Interaction profiles of the *MYC* promoter in GM and My-La H3K27ac HiChIP at 10-kb resolution. T cell H3K27ac ChIP-seq and ATAC-seq data are from naive T cells. **(e)** Top, CRISPRi validation in GM cells of GM- and My-La-biased *MYC* enhancers. E-P, enhancer-promoter. Bottom, *MYC* RNA levels by qRT-PCR and cell growth rates in CRISPRi GM cells with targeting of cell-type-biased enhancers, the *MYC* promoter, and a non-targeting negative control ($n = 3$ biological replicates, each with 2 technical replicates). **(f)** Interaction profile of the *CD69* promoter in Jurkat H3K27ac HiChIP at 5-kb and 1-kb resolution. The 1-kb profile is focused on the window of the CRISPRa tiling screen. CRISPRa-validated regulatory regions in Jurkat cells are indicated²⁶. **(g)** Top, CRISPRa validation in Jurkat cells of *CD69* distal enhancers. Bottom, *CD69* RNA and protein levels in CRISPRa Jurkat cells with targeting of distal enhancers, the *CD69* promoter, the *KLRF2* promoter as a locus negative control, and a non-targeting negative control ($n = 2$ biological replicates, each with 2 technical replicates). In the box plots, each box extends from the 25th to the 75th percentile with a line representing the median, and whiskers extend to the minimum and maximum values. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$, **** $P < 0.0001$ one-way ANOVA followed by Dunnett's multiple-comparisons test against the non-targeting control; n.s., not significant.

also exhibited biased HiChIP signal, as expected. 58.5% of naive T cell-biased loops contained at least one naive T cell-biased HiChIP-seq peak (\log_2 (fold change) > 1) located on the anchors. Similarly, 66.7%

of T_H17 cell-biased and 67.8% of T_{reg} cell-biased interaction anchors were cell type specific in 1D (Supplementary Fig. 10a). Therefore, while on average ~64% of the differential EIS corresponds to changes




Figure 3 Dynamic 3D enhancer landscapes in T cell differentiation. (a) Conformational features observed by H3K27ac HiChIP. (b) HiChIP EIS in 913 differential interactions identified in T cell subtypes. Interactions are clustered by cell type specificity. (c) Cell-type-specific motif identification from ATAC-seq peaks in biased EIS anchors. (d) EIS bias quartiles for naive to T_H17 and naive to T_{reg} differentiation, with corresponding differential RNA gene expression rankings. (e) Interaction profile of the *BACH2* promoter at 5-kb resolution, demonstrating shared accessibility signal at naive-biased EIS. (f) Proportion of ATAC-seq peaks within HiChIP differential interaction anchors that are cell type specific (\log_2 (fold change) > 1) or shared across all three subtypes. (g) Global correlation of EIS and ATAC-seq fold change in different pairwise comparisons of T cell subsets.

in 1D data, ~36% is likely also driven by changes in 3D chromatin loop strength. To further assess the contribution of cell-type-specific 3D signal to EIS, we examined HiChIP 1D signal at differential EIS anchors. We found that HiChIP 1D signal correlated better with ChIP-seq signal than EIS, with a higher likelihood of differential ChIP-seq signal overlapping differential HiChIP 1D signal as compared to 3D signal, suggesting that EIS bias is in part driven by 3D changes (**Supplementary Fig. 10b**).

We asked whether the integration of reference cell line Hi-C data with primary T cell H3K27ac ChIP-seq data could recapitulate HiChIP EIS in primary T cells. We binned GM Hi-C loops with increasing primary T cell ChIP-seq signal at loop anchors and then determined the overlap of loops in each bin with loops derived from H3K27ac HiChIP. As expected, increased ChIP-seq signal at the Hi-C anchors led to increased overlap with the HiChIP loops. However, the overlap was lower in all T cell subtypes as compared to the same analysis performed using GM HiChIP data. These observations demonstrate that cell-type-specific 3D interactions can impact EIS independently of differences in 1D ChIP-seq signal (**Supplementary Fig. 10c**). Similarly, previously generated enhancer-promoter maps obtained from bulk T cells did not identify T cell subtype-specific interactions obtained using H3K27ac HiChIP. To assess the unique information obtained through cell-type-specific interaction maps, we compared promoter-capture Hi-C maps¹⁴ in bulk CD4⁺ T cells to H3K27ac HiChIP maps in naive T, T_H17, and T_{reg} cells. Strikingly, the most cell-type-specific loops in T_H17 and T_{reg} cells (16-fold enriched) demonstrated a low discovery rate in promoter-capture Hi-C T cells (11.83% in 415 loops and 13.83% in 373 loops, respectively; **Supplementary Fig. 10d**). Many of these subset-specific interactions included genomic loci encoding functionally important effector genes, such as *LRRC32*. The *LRRC32* locus contained T_{reg}-specific loops that were neither visualized in HiChIP maps from naive T or T_H17 cells nor in bulk CD4⁺ promoter-capture Hi-C maps (**Supplementary Fig. 10e**). Because primary human T_H17 and T_{reg} cells are present in human blood at low frequencies, it would also be challenging to generate subset-specific promoter-capture Hi-C maps with published promoter-capture Hi-C protocols. In summary, EIS is derived from a combination of 1D ChIP-seq signal and 3D interaction signal and cannot be accurately predicted from 3D maps in reference cell lines or unsorted primary cell data sets.

Cell-type-specific EIS can occur at sites of shared chromatin accessibility. Paired chromatin accessibility profiles from ATAC-seq³² for each T cell subset showed that most cell-type-specific loop anchors had equivalent chromatin accessibility across all three cell types (**Fig. 3e–g**). To illustrate this finding, we examined the *BACH2* promoter, which exhibited shared chromatin accessibility at enhancers but increased EIS in naive T cells (**Fig. 3e**). Globally, only 14.2%, 27.8%, and 16.5% of naive-, T_H17-, and T_{reg}-biased loops, respectively, contained at least one biased ATAC-seq peak (\log_2 (fold change) > 1) located on the anchors. Furthermore, the majority of cell-type-specific transcription factor motifs were observed in shared ATAC-seq peaks within differential interactions, highlighting the notion that these regions are functioning in T cell differentiation (**Fig. 3f,g**). Altogether, these results suggest that, in highly related—yet functionally distinct—cell types, a portion of transcriptional control is achieved through differential chromosome looping, rather than differential chromatin accessibility. This finding is consistent with previous studies that demonstrated that T cell subset-specific transcription factors, such as FOXP3, act predominantly at pre-accessible chromatin sites to establish subset-specific gene expression³³.

Enhancer interactions link disease variants to target genes

The high specificity of EIS enabled us to identify putative target genes of autoimmune disease risk loci in functionally relevant T cell subsets. To achieve this, we used a previously described list of putatively causal variants associated with 21 autoimmune diseases, known as PICS SNPs, which were fine-mapped on the basis of dense genotyping data²⁵. We determined that PICS autoimmune disease-associated SNPs were significantly enriched in T cell loop anchors, with variants for specific autoimmune diseases showing greater than fivefold enrichment as compared to a shuffled control loop set (**Supplementary Fig. 11**). Next, we constructed a set of all possible connections between autoimmune disease risk SNPs and TSSs within 1 Mb and measured the EIS for each SNP–TSS pair (**Fig. 4a**). We aggregated these signals to determine the overall interaction activity in each T cell subtype for each disease (**Fig. 4b**). We observed high interaction strength enrichments and cell type specificity for autoimmune disease-associated SNPs, but low enrichment and cell type specificity for variants associated with non-immune traits (**Fig. 4b**). To further visualize HiChIP bias in shared or differential enhancers, we analyzed SNP–TSS interactions grouped by their presence near H3K27ac ChIP-seq peaks (**Supplementary Fig. 12a,b**). We observed a large number of active SNP–TSS pairs that were present in regulatory regions that were shared by T effector cell types (T_{reg} and T_H17 cells), whereas relatively less EIS was observed for SNPs located in cell-type-specific enhancers, supporting the concept that many autoimmune disease variants impact common T cell effector/activation pathways^{25,34}. Notably, SNPs present in enhancers shared by all three cell types could still be distinguished by HiChIP bias (**Supplementary Fig. 12a,b**). For example, although we could not detect cell type bias at risk loci for alopecia areata using H3K27ac ChIP-seq data (**Supplementary Fig. 12a,b** and ref. 3), H3K27ac HiChIP identified increased SNP–TSS activity in T_{reg} cells at shared T cell enhancers, consistent with several studies identifying the crucial role of this cell type in disease pathogenesis³⁵. Of note, autoimmune disease signal enrichments were not readily apparent from 1D H3K27ac ChIP-seq peaks, aggregated ChIP-seq signal within the TAD containing the SNP, or cell line H3K27ac HiChIP data sets (**Fig. 4b** and **Supplementary Fig. 12c**). Therefore, examining 3D disease variant interactions may capture cell type biases more robustly than 1D epigenomic data. Finally, to validate our findings with an orthogonal data set, we performed SNP–TSS EIS analysis on an overlapping set of autoimmune disease-associated SNPs obtained from the National Heart, Lung, and Blood Institute (NHLBI) GRASP catalog. We observed a similar pattern of enrichment for T cell subset-specific HiChIP signal in disease-associated variants (**Supplementary Fig. 12d**).

We leveraged HiChIP to identify potential gene targets of intergenic SNPs, which have classically been paired to the nearest neighboring gene. We overlapped the SNP–TSS pairs with loops to call a discrete set of target pairs. We then performed differential analysis on the SNP–TSS loops to ascertain bias for specific T cell subsets (**Fig. 4c** and **Supplementary Table 5**). Examples of biased SNP–TSS pairs included *FOXO1* in naive T cells (rs9603754), *BATF* (rs2300604) in memory T cells, *CTLA4* (rs10186048) in T_{reg} cells, and *IL2* (rs7664452) in T_H17 cells (**Fig. 4c** and **Supplementary Table 5**). Next, we sought to characterize the connectivity landscape of the SNP–TSS loops. We identified an average of 1.75 gene targets per autoimmune disease-associated SNP (ranging from 0 to over 10 target genes), whereas variants for non-immune traits did not demonstrate an increase in the number of targets (0.33 genes per SNP; **Supplementary Fig. 12e**). For 684 autoimmune disease intergenic SNPs, we identified a total of 2,597 HiChIP target genes, representing a fourfold increase in the number of target genes for known disease-associated SNPs (**Fig. 4d**). Only 367 (~14%)




Figure 4 HiChIP identifies cell type specificity and target genes of autoimmune disease-associated variants. **(a)** Generation of a loop set between all autoimmune disease SNPs and gene promoters within a 2-Mb region. **(b)** H3K27ac ChIP and HiChIP signal bias in T cell subtypes for SNP–TSS pairs. For each bin, PICS SNPs are tagged by H3K27ac only in the concordant cell type for the bias tested. SNPs are grossly divided into associations with autoimmune diseases or control, non-immune traits. Asterisks indicate FDR < 5%. **(c)** EIS bias of SNP–TSS loops (with nearest gene annotated) in T_{H17} and T_{reg} subsets (memory T cells) versus naive T cells and T_{H17} versus T_{reg} cells. Percentages represent the percentage of SNP–TSS interactions that demonstrate biased HiChIP signal in the indicated cell type (\log_2 (fold change) > 1). MS, multiple sclerosis. **(d)** Number of HiChIP gene targets versus nearest-gene predictions for all looping non-genic autoimmune disease SNPs as well as SNPs for specific diseases. **(e)** Global validation of HiChIP SNP gene targets. Synthetic SNP–TSS pairs were generated from each CD4⁺ eQTL SNP to its associated gene and compared to both a distance-matched shuffled SNP–TSS pair and a liver (L) eQTL SNP–TSS pair. *P* values were calculated by Kolmogorov–Smirnov test. **(f)** HiChIP target gene RNA levels by qRT–PCR in CRISPRi My-La cells with targeting of SNP-containing enhancers of interest, as well as positive-control sgRNAs to the HiChIP target promoters and a non-targeting negative control (*n* = 3 biological replicates, each with 2 technical replicates). RA, rheumatoid arthritis; PBC, primary biliary cirrhosis. * $P < 0.05$; ** $P < 0.01$, two-tailed Student's *t* test. In box plots, each box extends from the 25th to the 75th percentile with a line representing the median, and whiskers extend to the minimum and maximum values.

of all targets were the nearest gene to the SNP, while approximately ~86% of SNPs skipped at least one gene to reach a predicted target TSS (**Supplementary Fig. 12e**). Furthermore, approximately ~45% of SNP to HiChIP target interactions had increased signal as compared to the interaction between the same SNP and the nearest gene, despite distance biases.

Target gene validation by eQTL and CRISPRi

HiChIP enhancer–target gene interactions can be validated using previously identified point mutations that alter expression at distantly located genes in T cells—that is, expression quantitative trait loci (eQTLs)³⁶. For example, the celiac disease–associated SNP rs2058660 impacts expression of the inflammatory cytokine receptor genes *IL18RAP*, *IL18R1*, *IL1RL1*, and *IL1RL2*, which are known regulators of intestinal T cell differentiation and response³⁷. HiChIP EIS showed contacts between rs2058660 and the promoters of each of these predicted target genes (**Supplementary Fig. 13a**). Similarly, the Crohn's disease risk variant rs6890268 and the multiple sclerosis risk variant rs12946510 impact the expression of *PTGER4* and *IKZF3*, respectively, and H3K27ac HiChIP also demonstrated clear contacts between these SNPs and their predicted promoters (**Supplementary Fig. 13a**). Globally, HiChIP contact signal was increased in eQTLs in T cells as compared to a distance-matched background loop set ($P < 2.2 \times 10^{-16}$; **Fig. 4e**) or to eQTLs identified in an unrelated cell type (liver; $P < 2.2 \times 10^{-16}$). The overlap of HiChIP and eQTL loci provides support for chromosome interactions as a physical basis for distal eQTLs^{10–12} and further validates the HiChIP approach to assign enhancer–target gene relationships.

We next sought to directly validate HiChIP SNP–gene target interactions using CRISPRi in My-La cells. First, we focused on three loci of interest in primary T cells and then confirmed that the SNP–TSS loops were also present in My-La cells (**Fig. 4f** and **Supplementary Fig. 13b**). We then targeted sgRNAs to these SNP-containing enhancers, as well as positive-control sgRNAs to the HiChIP target gene promoters and a non-human-genome-targeting negative control. As expected, we observed a significant reduction in RNA levels for the HiChIP target genes upon CRISPRi of the corresponding SNP-containing enhancers (**Fig. 4f**).

Fine-mapping of disease-associated DNA variants

As SNP–TSS HiChIP signal is capable of identifying the target genes of candidate SNPs, we asked whether TSS–SNP HiChIP signals could also be used to nominate functional causal variants within haplotype blocks in a reciprocal manner. We first performed a proof-of-principle analysis using fine-mapped SNPs associated with inflammatory bowel disease (IBD)³⁸ or type 1 diabetes (T1D)³⁹ as well as high-confidence PICS SNPs and examined EIS from putatively causal SNPs to all gene promoters within 300 kb. EIS from putatively causal SNPs to gene promoters was significantly higher than EIS from a distance-matched set of SNPs within the same linkage disequilibrium (LD; $r^2 \geq 0.8$) block to gene promoters ($P = 2.4 \times 10^{-15}$, 8.7×10^{-8} , and 3.9×10^{-3} for IBD fine-mapped SNPs, T1D fine-mapped SNPs, and high-confidence PICS SNPs, respectively; **Fig. 5a** and **Supplementary Fig. 14a**). Next, we assessed the fine-mapping ability of HiChIP EIS at individual loci of interest. We focused on IBD- and multiple sclerosis–associated SNPs neighboring the *PTGER4* and *SATB1* loci and performed v4C analysis anchored at the gene promoters. We calculated EIS signal at 1-kb resolution and identified specific regions within the LD blocks that contained the highest EIS to the target promoters, positioning the likely causal SNPs within these regions (**Fig. 5b** and **Supplementary Fig. 14b**). For example, at the *PTGER4* locus (**Fig. 5b**), the ~160-kb

genomic interval spanned by LD SNPs in association with Crohn's disease was refined to two bins of 3 kb and 4 kb, which both contained PICS SNPs.

We asked whether complex disease–associated loci containing more than one gene could be fine-mapped using HiChIP. We focused on two disease-associated enhancers in between the *STAT1* and *STAT4* gene promoters (**Fig. 5c**). These two genes encode transcription factors with distinct roles in immune regulation. Signal transducer and activator of transcription 1 (STAT1) is critical for type I interferon (IFN) and IFN- γ signaling, whereas STAT4 induces T_H1 differentiation and IFN- γ expression⁴⁰. We investigated bias of these enhancers to *STAT1* and *STAT4* and found that, despite comparable linear distances and 1D signals at the promoters, the enhancers were biased to interact with *STAT4*. Next, we fine-mapped the disease-associated SNPs within this locus using 1-kb-resolution EIS from the *STAT4* promoter and narrowed down candidate functional variants within the two enhancers (**Fig. 5c**). In summary, HiChIP EIS can nominate functional causal variants within haplotype blocks, and two-way analysis of target gene identification from an enhancer of interest and high-resolution interaction maps of that enhancer with its target gene can be used to fine-map disease-associated loci containing several candidate genes.

Allelic target gene bias of cardiovascular disease variants

Finally, we asked whether this approach could be applied broadly to other categories of human disease and whether we could directly test SNP–TSS associations using allele-specific HiChIP. We generated high-resolution enhancer–promoter maps from primary human coronary artery smooth muscle cells (HCASMCs), which can be used to inform on variants linked to cardiovascular diseases⁴¹. First, to validate cell type specificity, we examined the gene promoter for *TCF21*, a transcription factor required for the differentiation of HCASMCs⁴², and observed enrichment of HCASMC EIS relative to naive T cells (**Fig. 6a**). We next examined the 9p21.3 locus, which harbors risk associations with several cardiovascular disorders^{43–45}. We found that the promoters of all three genes in the locus interacted with one another and with CAD-variant-containing enhancers located approximately 100 kb upstream of the *CDKN2B* promoter (**Supplementary Fig. 15**). We then generated SNP–TSS target lists using CAD-associated SNPs identified in the CARDIoGRAMplusC4D study⁴⁶. We again performed differential analysis on the SNP–TSS loops to ascertain bias for HCASMCs versus naive T cells (**Fig. 6b**). Overall, 75.1% of HCASMC-biased SNP–TSS pairs involved CAD-associated SNPs, whereas only 5.5% of naive T cell-biased SNP–TSS pairs were CAD SNP–TSS loops. Next, we examined the connectivity of the HCASMC SNP–TSS contacts and identified 1,062 gene targets, of which only 120 (~11%) mapped to the nearest gene. Furthermore, approximately 89% skipped at least one gene to reach a predicted target TSS, and 64% of SNPs were mapped to more than a single gene target.

We took advantage of genome phasing information in HCASMCs to measure enhancer–promoter interactions at allele-specific CAD-associated SNPs, allowing us to examine the functional consequence of a risk variant as compared to its alternative allele in the same nucleus. First, 4.2% of high-confidence loops in HCASMCs with no observed mapping bias in the anchors exhibited significant allelic bias (FDR < 0.05; **Fig. 6c**), consistent with the frequency of allelic imbalance of RNA expression and prior evidence of allele-specific regulation of specific enhancer–promoter interactions^{47,48}. We leveraged this global enhancer–promoter allelic bias to examine the effect of a risk-associated variant as compared to its control alternative allele for a set of CAD-associated SNP–target gene pairs (**Fig. 6d**)⁴⁹. We found




Figure 5 Fine-mapping of GWAS-identified variants using H3K27ac HiChIP. **(a)** Global validation of HiChIP signal at putatively causal SNPs (confident) versus corresponding SNPs in LD (LD SNPs; $r^2 \geq 0.8$) for T_H17 cells. SNP–TSS pairs were generated from published fine-mapping data sets, in comparison to a distance-matched SNP–TSS pair set in the same LD block. P values were calculated by Kolmogorov–Smirnov test. **(b)** Interaction profile of the *PTGER4* promoter and a 1-kb-resolution visualization of the SNP-containing enhancer of interest. SNPs in LD ($r^2 \geq 0.8$) correspond to GRASP SNPs (genome-wide significance $P < 1 \times 10^{-8}$). The highlighted SNP was identified in both the high-confidence PICS and GRASP data sets. UC, ulcerative colitis. **(c)** Interaction profiles of the *STAT1* and *STAT4* promoters, with 1-kb-resolution visualizations of the SNP-containing enhancers of interest. 1D signal contributions at the *STAT1* and *STAT4* promoters are highlighted. Highlighted SNPs are PICS SNPs closest to focal EIS for *STAT4*.

that many risk alleles disrupted enhancer–target gene interactions, but a subset of pathogenic SNPs increased enhancer–target gene interaction. At *CAD* risk variant rs1537373 in the 9p21.3 locus, the risk allele (T) showed increased EIS to the *CDKN2A* promoter as well as an additional enhancer within the long noncoding RNA

ANRIL gene relative to the reference allele (G) (**Fig. 6e**). We further observed increased EIS of the *CAD* risk variant rs4562997 to an additional *SMAD3* enhancer 10 kb downstream of the TSS (**Fig. 6e**). The ability to resolve enhancer connectomes of the risk and reference alleles in the same nucleus demonstrates that the mutated base in the




Figure 6 HiChIP identifies allelic bias to target genes for cardiovascular disease risk variants. (a) Interaction profile of the *TCF21* gene promoter for H3K27ac HiChIP of HCASMCs and naive T cells. (b) EIS bias between HCASMCs and naive T cells in a union set of CARDIoGRAMplusC4D CAD and PICS autoimmune disease SNP-TSS loops. Percentages represent the percent of SNP-TSS interactions that demonstrate biased HiChIP signal in the indicated cell type (\log_2 (fold change) > 1). (c) Quantile-quantile plot of allelic EIS imbalance in high-confidence loops. Allelic mapping biased loops were identified through simulation and removed before EIS analysis. (d) EIS bias between CAD risk variants and their alternative alleles to eQTL-associated target genes. (e) Allele-specific HiChIP interaction profiles at the 9p21.3 and *SMAD3* loci at 10-kb resolution to examine the functional consequence of a risk variant as compared to its alternative allele. ATAC-seq and ChIP-seq data sets shown are from ref. 41.

risk allele suffices to alter enhancer looping in *cis* in disease-relevant primary cells.

DISCUSSION

Here we developed an approach to define the high-resolution landscape of enhancer-promoter regulation in primary human cells. We find that enhancer-promoter contacts are highly dynamic in related cell types and often involve genomic elements with shared accessibility. Accordingly, many complex features of the 3D enhancer connectome cannot simply be predicted from 1D data, demonstrating that mapping conformation in primary cells can identify new regulatory connections underlying gene function in human disease. We take advantage of this principle to chart the connectivity of autoimmune and cardiovascular disease genome-wide association study (GWAS)-identified SNPs and link SNPs to hundreds of potential target genes. Although non-genic SNPs have previously been paired with their closest neighboring gene, we find that the majority of these variants can engage in long-distance interactions, including skipping several promoters to predicted target genes, connecting to multiple genes, or acting in concert with enhancer cliques to contact a single gene. Further use of this approach will help to clarify hidden mechanisms of human disease that are driven by genetic perturbations in non-protein-coding DNA elements, which can now be linked to their cognate gene targets in primary cells.

METHODS

Methods, including statements of data availability and any associated accession codes and references, are available in the [online version of the paper](#).

Note: Any Supplementary Information and Source Data files are available in the online version of the paper.

ACKNOWLEDGMENTS

We thank members of the Chang and Greenleaf laboratories for helpful discussions and J. Tumey for artwork. We thank J. Engreitz, M. Pjanic, and C. Miller for assistance interpreting their published data sets. We thank X. Ji and J. Collier at the Stanford Functional Genomics Facility. We thank Agilent Technologies for generating oligonucleotide pools for cloning of the CRISPRa gRNAs. We thank the UC Berkeley High-Throughput Screening Facility and Flow Cytometry Facility. This work was supported by US National Institutes of Health (NIH) grants P50HG007735 (H.Y.C. and W.J.G.) U19AI057266 (W.J.G.), and 1UM1HG009436 (W.J.G.), the Human Frontier Science Program (W.J.G.), the Rita Allen Foundation (W.J.G.), and the Scleroderma Research Foundation (H.Y.C.). M.R.M. and E.A.B. acknowledge support from the National Science Foundation Graduate Research Fellowship. A.T.S. is a Cancer Research Institute Irvington Fellow supported by the Cancer Research Institute. B.G.G. was supported by an IGI-AstraZeneca Postdoctoral Fellowship. M.R.C. is supported by a grant from the Leukemia & Lymphoma Society Career Development Program. J.E.C. was supported by the Li Ka Shing Foundation and the Heritage Medical Research Institute. W.J.G. and A.M. are Chan Zuckerberg Biohub investigators. Sequencing was performed by the Stanford Functional Genomics Facility (NIH S10OD018220).

AUTHOR CONTRIBUTIONS

M.R.M., A.T.S., W.J.G., and H.Y.C. conceived the project. M.R.M., A.T.S., J.T., and R.L. performed all genomics assays with help from T.N., M.R.C., N.S., and R.A.F. A.T.S. performed all sorting for experiments. B.G.G., S.W.C., M.R.M., M.L.N., K.R.K., and D.R.S. performed all CRISPR validation experiments. E.A.B., C.D., M.R.M., and J.X. analyzed HiChIP data. J.G., A.T.S., and Y.W. analyzed ATAC-seq data. A.J.R. and P.G.G. analyzed GWAS SNPs in HiChIP data. A.K., P.A.K., A.M., J.E.C., T.Q., W.J.G., and H.Y.C. guided experiments and data analysis. M.R.M., A.T.S., E.A.B., C.D., W.J.G., and H.Y.C. wrote the manuscript with input from all authors.

COMPETING FINANCIAL INTERESTS

The authors declare competing financial interests: details are available in the [online version of the paper](#).

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>. Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

- Dixon, J.R. *et al.* Topological domains in mammalian genomes identified by analysis of chromatin interactions. *Nature* **485**, 376–380 (2012).
- van Arensbergen, J., van Steensel, B. & Bussemaker, H.J. In search of the determinants of enhancer–promoter interaction specificity. *Trends Cell Biol.* **24**, 695–702 (2014).
- Lieberman-Aiden, E. *et al.* Comprehensive mapping of long-range interactions reveals folding principles of the human genome. *Science* **326**, 289–293 (2009).
- Rao, S.S.P. *et al.* A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. *Cell* **159**, 1665–1680 (2014).
- Fulco, C.P. *et al.* Systematic mapping of functional enhancer–promoter connections with CRISPR interference. *Science* **354**, 769–773 (2016).
- Altshuler, D., Daly, M.J. & Lander, E.S. Genetic mapping in human disease. *Science* **322**, 881–888 (2008).
- Kumar, V. *et al.* Human disease-associated genetic variation impacts large intergenic non-coding RNA expression. *PLoS Genet.* **9**, e1003201 (2013).
- Edwards, S.L., Beesley, J., French, J.D. & Dunning, A.M. Beyond GWAS: illuminating the dark road from association to function. *Am. J. Hum. Genet.* **93**, 779–797 (2013).
- Welter, D. *et al.* The NHGRI GWAS Catalog, a curated resource of SNP–trait associations. *Nucleic Acids Res.* **42**, D1001–D1006 (2014).
- Smemo, S. *et al.* Obesity-associated variants within *FTO* form long-range functional connections with *IRX3*. *Nature* **507**, 371–375 (2014).
- Claussnitzer, M. *et al.* *FTO* obesity variant circuitry and adipocyte browning in humans. *N. Engl. J. Med.* **373**, 895–907 (2015).
- Grubert, F. *et al.* Genetic control of chromatin states in humans involves local and distal chromosomal interactions. *Cell* **162**, 1051–1065 (2015).
- Mifsud, B. *et al.* Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C. *Nat. Genet.* **47**, 598–606 (2015).
- Javierre, B.M. *et al.* Lineage-specific genome architecture links enhancers and non-coding disease variants to target gene promoters. *Cell* **167**, 1369–1384 (2016).
- Sanjana, N.E. *et al.* High-resolution interrogation of functional elements in the noncoding genome. *Science* **353**, 1545–1549 (2016).
- Mumbach, M.R. *et al.* HiChIP: efficient and sensitive analysis of protein-directed genome architecture. *Nat. Methods* **13**, 919–922 (2016).
- Heintzman, N.D. *et al.* Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. *Nat. Genet.* **39**, 311–318 (2007).
- Creyghton, M.P. *et al.* Histone H3K27ac separates active from poised enhancers and predicts developmental state. *Proc. Natl. Acad. Sci. USA* **107**, 21931–21936 (2010).
- Rada-Iglesias, A. *et al.* A unique chromatin signature uncovers early developmental enhancers in humans. *Nature* **470**, 279–283 (2011).
- Ferraro, A. *et al.* Interindividual variation in human T regulatory cells. *Proc. Natl. Acad. Sci. USA* **111**, E1111–E1120 (2014).
- Arvey, A. *et al.* Genetic and epigenetic variation in the lineage specification of regulatory T cells. *eLife* **4**, e07571 (2015).
- Bettelli, E. *et al.* Reciprocal developmental pathways for the generation of pathogenic effector T_H17 and regulatory T cells. *Nature* **441**, 235–238 (2006).
- Acosta-Rodriguez, E.V. *et al.* Surface phenotype and antigenic specificity of human interleukin 17–producing T helper memory cells. *Nat. Immunol.* **8**, 639–646 (2007).
- Morita, R. *et al.* Human blood CXCR5⁺CD4⁺ T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. *Immunity* **34**, 108–121 (2011).
- Farh, K.K.-H. *et al.* Genetic and epigenetic fine mapping of causal autoimmune disease variants. *Nature* **518**, 337–343 (2015).
- Simeonov, D.R. *et al.* Discovery of stimulation-responsive immune enhancers with CRISPR activation. *Nature* **549**, 111–115 (2017).
- Engreitz, J.M. *et al.* Local regulation of gene expression by lncRNA promoters, transcription and splicing. *Nature* **539**, 452–455 (2016).
- Dao, L.T.M. *et al.* Genome-wide characterization of mammalian promoters with distal enhancer functions. *Nat. Genet.* **49**, 1073–1081 (2017).
- Ernst, J. & Kellis, M. ChromHMM: automating chromatin-state discovery and characterization. *Nat. Methods* **9**, 215–216 (2012).
- Sanborn, A.L. *et al.* Chromatin extrusion explains key features of loop and domain formation in wild-type and engineered genomes. *Proc. Natl. Acad. Sci. USA* **112**, E6456–E6465 (2015).
- Li, G. *et al.* Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. *Cell* **148**, 84–98 (2012).
- Buenrostro, J.D., Giresi, P.G., Zaba, L.C., Chang, H.Y. & Greenleaf, W.J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. *Nat. Methods* **10**, 1213–1218 (2013).
- Samstein, R.M. *et al.* Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification. *Cell* **151**, 153–166 (2012).
- Ye, C.J. *et al.* Intersection of population variation and autoimmunity genetics in human T cell activation. *Science* **345**, 1254665 (2014).
- Petukhova, L. *et al.* Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. *Nature* **466**, 113–117 (2010).
- Raj, T. *et al.* Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. *Science* **344**, 519–523 (2014).
- Schiering, C. *et al.* The alarmin IL-33 promotes regulatory T-cell function in the intestine. *Nature* **513**, 564–568 (2014).
- Huang, H. *et al.* Fine-mapping inflammatory bowel disease loci to single-variant resolution. *Nature* **547**, 173–178 (2017).
- Onengut-Gumuscu, S. *et al.* Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. *Nat. Genet.* **47**, 381–386 (2015).
- O'Shea, J.J., Lahesmaa, R., Vahedi, G., Laurence, A. & Kanno, Y. Genomic views of STAT function in CD4⁺ T helper cell differentiation. *Nat. Rev. Immunol.* **11**, 239–250 (2011).
- Miller, C.L. *et al.* Integrative functional genomics identifies regulatory mechanisms at coronary artery disease loci. *Nat. Commun.* **7**, 12092 (2016).
- Nurnberg, S.T. *et al.* Coronary artery disease associated transcription factor TCF21 regulates smooth muscle precursor cells that contribute to the fibrous cap. *PLoS Genet.* **11**, e1005155 (2015).
- McPherson, R. *et al.* A common allele on chromosome 9 associated with coronary heart disease. *Science* **316**, 1488–1491 (2007).
- Helgadottir, A. *et al.* A common variant on chromosome 9p21 affects the risk of myocardial infarction. *Science* **316**, 1491–1493 (2007).
- Clarke, R. *et al.* Genetic variants associated with Lp(a) lipoprotein level and coronary disease. *N. Engl. J. Med.* **361**, 2518–2528 (2009).
- CARDIoGRAMplusC4D Consortium. Large-scale association analysis identifies new risk loci for coronary artery disease. *Nat. Genet.* **45**, 25–33 (2013).
- Leung, D. *et al.* Integrative analysis of haplotype-resolved epigenomes across human tissues. *Nature* **518**, 350–354 (2015).
- Dixon, J.R. *et al.* Chromatin architecture reorganization during stem cell differentiation. *Nature* **518**, 331–336 (2015).
- Franzén, O. *et al.* Cardiometabolic risk loci share downstream *cis*- and *trans*-gene regulation across tissues and diseases. *Science* **353**, 827–830 (2016).

ONLINE METHODS

Human subjects. This study was approved by the Stanford University Administrative Panels on Human Subjects in Medical Research, and written informed consent was obtained from all participants.

Cell culture and primary T cell isolation. Mouse ES cells (v6.5, Novus Biologicals, NBP1-41162) were cultured in Knockout DMEM (Gibco) supplemented with 15% FBS and leukemia inhibitory factor (LIF; Millipore) to 80% confluence. GM12878 (Coriell), Jurkat, and My-La (CD4⁺) cells (ATCC) were grown in RPMI 1640 (Gibco) supplemented with 15% FBS to a concentration of 500,000 to 1 million cells/ml. Normal donor human peripheral blood cells were obtained fresh from AllCells. CD4⁺ T cells were enriched from peripheral blood using RosetteSep Human CD4⁺ T Cell Enrichment Cocktail (StemCell Technology). For CD4⁺ T helper cell subtypes, naive T cells were sorted as CD4⁺CD25⁻CD45RA⁺ cells, T_H17 cells were sorted as CD4⁺CD25⁻CD45RA⁻CCR6⁺CXCR5⁻ cells, and T_{reg} cells were sorted as CD4⁺CD25⁺CD127^{lo} cells. Antibodies used for FACS included the following: PerCP/Cy5.5 anti-CD45RA (BioLegend, 304122), Brilliant Violet 510 anti-CD127 (BioLegend, 351331), APC/Cy7 anti-CD4 (BioLegend, 344616), PE anti-CCR6 (BioLegend, 353410), FITC anti-CD25 (BioLegend, 302603), Brilliant Violet 421 anti-CXCR3 (BioLegend, 353715), and BB515 anti-CXCR5 (BD Biosciences, 564625). For HiChIP experiments, 500,000 to 1 million cells were sorted into RPMI medium supplemented with 10% FCS. For ATAC-seq experiments, 55,000 cells were sorted into RPMI medium supplemented with 10% FCS. Post-sort purities of >95% were confirmed by flow cytometry for each sample.

A primary HCASMC line derived from a normal human donor heart was purchased from Cell Applications (350-05A) and cultured in smooth muscle growth medium (Lonza, CC-3182) supplemented with hEGF, insulin, hFGF-b, and 5% FBS. Cells were grown according to Lonza's instructions.

Cell fixation. Detached cell lines or sorted CD4⁺ T cells were pelleted and resuspended in fresh 1% formaldehyde (Thermo Fisher) at a volume of 1 ml of formaldehyde per 1 million cells. Cells were incubated at room temperature for 10 min with rotation. Glycine was added at a final concentration of 125 mM to quench the formaldehyde, and cells were incubated at room temperature for 5 min with rotation. Finally, cells were pelleted and washed with PBS, pelleted again, and stored at -80 °C or immediately taken into the HiChIP protocol.

HiChIP. The HiChIP protocol was performed as previously described, using antibody to H3K27ac (Abcam, ab4729) or CTCF (Abcam, ab70303)¹⁶ with the following modifications. For primary T cells, we performed HiChIP on as many cells as we could obtain from a blood donation—approximately 500,000 to 1 million cells per T cell subtype per replicate. We performed 2 min of sonication, did not carry out Protein A bead preclearing, used 4 µg of antibody to H3K27ac (Abcam, ab4729), and captured the chromatin-antibody complex with 34 µl of Protein A beads (Thermo Fisher). Qubit quantification following ChIP ranged from 5–25 ng depending on the cell type and amount of starting material. The amount of Tn5 used and number of PCR cycles performed were based on the post-ChIP Qubit amounts, as previously described¹⁶.

Twenty-five million cell line libraries were generated as previously described¹⁶. For mouse ES cell samples with low cell numbers, we performed 2 min of sonication and did not carry out Protein A bead preclearing. Either 4 µg or 2 µg of antibody to H3K27ac (Abcam, ab4729) was used for ChIP in 500,000 or 100,000/50,000 cells, respectively, and the chromatin-antibody complex was captured with 34 (500,000 cells) or 20 (100,000/50,000 cells) µl of Protein A beads. Post-ChIP Qubit quantification for the 25 million cell samples was approximately 1.5 µg. For lower cell numbers, quantification was 30, 10, and 5 ng for 500,000, 100,000, and 50,000 cells, respectively. The amount of Tn5 used and the number of PCR cycles performed were based on the post-ChIP Qubit amounts, as previously described.

HiChIP samples were size selected by PAGE purification (300–700 bp) for effective paired-end tag mapping and were therefore removed of all primer contamination that would contribute to recently reported 'index switching' on the Illumina HiSeq 4000 sequencer⁵⁰. All libraries were sequenced on the Illumina HiSeq 4000 instrument to an average depth of 500–600 million total reads.

HiChIP data processing. HiChIP paired-end reads were aligned to the hg19 or mm9 genome using the HiC-Pro pipeline⁵¹. Default settings were used to remove duplicate reads, assign reads to MboI restriction fragments, filter for valid interactions, and generate binned interaction matrices. HiC-Pro filtered reads were then processed into a .hic file using the hicpro2juicebox function. The Juicer pipeline HiCCUPS tool was used to identify high-confidence loops⁴ using the same parameters as for the GM12878 *in situ* Hi-C map: hic-cups -m 500 -r 5000,10000 -f 0.1,0.1 -p 4,2 -i 7,5 -d 20000,20000 .hic_input HiCCUPS_output. For T cell Juicer loops, performing the default Juicer calls resulted in a high rate of false positives upon visual inspection of the interaction matrix. We therefore called loops with the same HiCCUPS parameters in two biological replicates for each T cell subtype and then filtered loops for those that were reproducibly called in both replicates. In addition, we removed all loops greater than 1 Mb in length.

ID signal enrichment and peak calling were generated from the HiC-Pro filtered contacts file. Intrachromosomal contacts were filtered, and both anchors were extended by 75 bp. The combined bed file containing both anchors was then used to generate bigwigs for visualization in the WashU Epigenome Browser or call peaks using MACS2.

Allele-specific HiChIP data processing was achieved using HiC-Pro's allele-specific analysis features⁵¹. First, HCASMC phasing data⁴¹ were used to mask the hg19 genome and make indexes. HiC-Pro settings were similar to those described above, with the exception that reads were aligned to the masked genome and then assigned to a specific allele on the basis of phasing data.

Interaction matrices and virtual 4C visualization. HiChIP interaction maps were generated with Juicebox using KR matrix balancing and visualized using Juicebox software at 500-kb, 25-kb, 10-kb, and 5-kb resolution as indicated in each analysis⁴. For 1-kb profiles, raw matrix counts were visualized in Java TreeView.

v4C plots were generated from dumped matrices generated with Juicebox. The Juicebox tools dump command was used to extract the chromosome of interest from the .hic file. The interaction profile of a specific 5-kb or 10-kb bin containing the anchor was then plotted in R. Replicate reproducibility was visualized with the mean profile shown as a line and the shading surrounding the mean representing the s.d. between replicates. For the HCASMC data, we observed low read coverage for allele-specific v4Cs at loci of interest. This is due to the density of SNPs for this genotype and a low number of reads containing a phased SNP. We thus could not observe interaction profiles when visualizing separate replicates with s.d. We therefore used pseudoreplicates for the HCASMC v4C visualizations⁵².

High-confidence Juicer loop calls were loaded into the WashU Epigenome Browser along with corresponding ATAC-seq profiles and publically available H3K27ac ChIP-seq data from the Roadmap Epigenomics Project. Browser shots from WashU track sessions were then included in v4C and interaction map anecdotes.

Differential analysis of HiCCUPS loop calls. Juicer loop calls from the three T cell subtypes were initially combined into a union set of T cell loops. Loop signal was then obtained for the biological replicates of each T cell subtype. Vanilla coverage square root (VCsqr) normalized signal for the interaction matrix of each biological replicate using the Juicebox tools dump command. Normalized signal was then assigned to the union loop set in each replicate.

VCsqr signal per sample was quantile-quantile normalized under the assumption that overall signal was identically distributed across all samples. Following normalization, samples for naive T, T_H17 and T_{reg} cells had Pearson correlations of 0.938, 0.942, and 0.934, respectively. Principal-component analysis (PCA) was performed using the prcomp function in R, which demonstrated that the first principal component, which exhibited nearly identical loadings across the six samples, explained 93% of the variance across the six samples. This was taken to represent the shared signal across cell types. Principal components 2–4 explained 2.2%, 2.0%, and 1.4%, respectively.

To study cell-type-specific looping, the residual signal per loop was taken after projecting the loop onto the unit vector along the diagonal (equal signal per cell type). Cell-type-specific and differential looping analysis were performed with the top and bottom 5% of the distributions of either residual signal or differences between cell type residual signals. Hierarchical clustering

was performed using the union of all differential loops in these extremes and using 1 minus the Pearson correlation as the distance metric. Quantile–quantile plots were generated by permuting residuals from the same cell type or individual and summing them and using this distribution to calculate *P* values for the observed sums.

In parallel, differential loops were called using edgeR for both the mouse ES and T cell data sets. Again, biological replicate loop signal was obtained across a union set of Juicer loops. We then used edgeR to identify loops with significant changes in signal among pairwise comparisons (FDR < 0.1, log₂ (fold change) > 1). Notably, inspection of differential loops identified from the two methods showed high concordance.

Gene density was calculated from Ensembl gene annotations. GC content was calculated per 10-kb bin using the BEDTools nuc function and aggregated as needed. Notably, Spearman correlation between the gene density of an entire chromosome and the number of differential loop anchors ($\rho = 0.914$) was much higher than the correlations between the variance in cell type signal per loop anchor and number of genes per 10-kb window ($\rho = 0.322$) and between differential loop anchors and gene density per 100-kb section ($\rho = 0.083$). Correlations between GC content and number of differential loops were similar at both the chromosome ($\rho = 0.729$) and 100-kb ($\rho = 0.148$) levels, but, while local GC content is likely to confound relative abundance, it is unclear how chromosome-wide GC content could have the same effect.

For mouse ES cell analysis of H3K27ac- and cohesin-mediated HiChIP, we performed edgeR to obtain the biased loops for each factor. To determine the functional bias of the top loops, overlap was determined between edgeR differential loop anchors and relevant ChIP-seq peaks. SMC1A ChIP-seq peaks were obtained from a published data set⁵³. CTCF, RNA polymerase II, and H3K27ac ChIP-seq peaks were obtained from the mouse ENCODE repository⁵⁴.

RNA expression analysis. Previously generated RNA-seq data⁵⁵ from naive T, T_{H17} and T_{reg} cells were downloaded as fastq files from ArrayExpress. Illumina adaptors were trimmed using CutAdapt, and Ensembl cDNA transcripts were quantified using kallisto. Sleuth was used to identify transcripts that were differentially expressed across cell types with FDR controlled at 5%. The mean TPM was calculated per cell type, and TSS differential looping quantiles at genes with nonzero expression were correlated with differential expression quantiles of the same genes. Only 10-kb segments of the genome that contained a single annotated gene were considered to avoid errors in attribution of looping signal per 10-kb bin. For genes with multiple annotated TSSs, the 10-kb bin corresponding to the median TSS was used. Significance was assessed by the cor.test function in R.

Distance-matched eQTL SNP–TSS comparisons. We obtained three groups of eQTL SNP–TSS pairs within 1 Mb for HiChIP EIS comparisons. The treatment group contained CD4⁺ T cell eQTL–TSS targets. We had two distance-matched groups as controls. The first control group contained CD4⁺ T cell eQTL SNP–random TSS pairs such that the distance between the eQTL SNP and random TSS differed by at most 5 kb with the treatment group. The second control group contained liver eQTL SNP–TSS targets that were also distance matched with the treatment group. The random eQTL SNP–TSS pairs were generated by individual chromosome, such that the numbers of control pairs and treatment pairs were the same for every chromosome. In total, there were 158,482 distance-matched eQTL–TSS pairs. We compared the 5-kb-resolution EIS values among the three eQTL SNP–TSS groups for all three T cell subtypes. Results showed that, in all cases, the EIS values between CD4⁺ T cell eQTL–TSS targets were significantly higher than the two control groups ($P < 1 \times 10^{-16}$, Kolmogorov–Smirnov test).

Distance-matched fine-mapped SNP–TSS comparisons. We obtained a list of putatively causal SNPs from the PICS SNP list²⁵ (PICS probability > 0.5), as well as fine-mapped SNPs associated with IBD³⁸ or T1D³⁹. Next, we obtained all SNPs in LD with each putatively causal SNP using European LD blocks determined by all SNPs with $r^2 \geq 0.8$ with the SNP being considered. For the fine-mapped (T1D/IBD) sets, using SNPs in LD with highly significant GWAS SNPs might mean that there are several SNPs of equal or greater significance in the control set, but we still expect enrichment relative to the LD block.

We collected all the synthetic pairs between the putatively causal immune disease-related SNPs (IBD, T1D, and PICS) and nearby genes within 300 kb. To perform the distance-matched EIS comparisons, for each fine-mapped SNP category, we selected the SNP–TSS control pairs that satisfied two constraints: (i) the selected control SNP was positioned at least 5 kb away from the fine-mapped SNP in the same LD block and (ii) the distance of the SNP–TSS control pair differed with the fine-mapped SNP and the target gene by at most 5 kb.

SNP–TSS loop analyses. We obtained 7,747 PICS SNPs that are associated with autoimmune disease or non-immune traits²⁵. 4,331 (55.9%) were associated with autoimmune disease, and 3,416 (44.1%) were associated with non-immune traits. In addition, we obtained a set of SNPs associated with six overlapping autoimmune diseases using the GRASP catalog (genome-wide significance $P < 1 \times 10^{-8}$).

We constructed a synthetic loop set for immune and non-immune SNPs and any TSS within 1 Mb of each SNP. We then assigned VCSqrt signal in each biological replicate of the three T cell subtypes to the synthetic loop set, as described above.

VCSqrt signal per sample was quantile–quantile normalized as above. In this analysis, we did not restrict to HiCCUPS-identified loops but instead examined all possible interactions between a SNP and a TSS within 1 Mb. Many of these interactions do not exist and therefore had little or no matrix-balanced signal supporting them. While we removed all SNP–TSS pairs below an average of 1 normalized read per sample from subsequent analyses, in general, these false interactions contributed little to the overall differential signal for a trait.

H3K27ac data were downloaded from the WashU Roadmap repository. PICS SNPs were taken from Farh *et al.*²⁵. Rather than requiring strict membership within H3K27ac peaks, PICS SNPs were labeled as active if they were within 8 kb of a peak, increasing the number of nominally functional SNPs from ~700 to ~3,200 per cell type, out of 7,735 total candidate SNPs.

Differential looping across cell types was assessed by one-sided *t* test per trait and activity partition if there were at least eight PICS SNP–TSS pairs in the partition. T_{H17} bias was defined as T_{H17} total loop signal minus naive T cell total loop signal; T_{reg} bias was defined as T_{reg} total loop signal minus naive T cell total loop signal; and naive T cell bias was defined as naive T cell total loop signal minus one-half times the T_{H17} and T_{reg} total loop signals. For **Supplementary Figure 12a,b,d**, naive T cell bias was assessed only using SNPs that were active in naive T cells, T_{H17} bias from SNPs active in T_{H17} and not naive T cells, and T_{reg} bias from SNPs active in T_{reg} and not naive T cells. *P* values were corrected for multiple-hypothesis testing by the Holm method using the p.adjust function in R. Bias assessed from SNPs with the opposing cell type specificities (for example, naive T cell bias using SNPs active in T_{H17} and T_{reg} cells but not naive T cells) yielded no significant hits after correction.

ATAC-seq. Cells were isolated and subjected to ATAC-seq as previously described¹⁶. Briefly, 55,000 cells were pelleted, resuspended in 50 μ l of lysis buffer (10 mM Tris-HCl, pH 7.4, 3 mM MgCl₂, 10 mM NaCl, 0.1% NP-40 (Igepal CA-630)), and immediately centrifuged at 500 r.c.f. for 10 min at 4 °C. The nuclei pellets were resuspended in 50 μ l of transposition buffer (25 μ l of 2 \times TD buffer, 22.5 μ l of distilled water, 2.5 μ l of Illumina Tn5 transposase) and incubated at 37 °C for 30 min. Transposed DNA was purified with the MinElute PCR Purification kit (Qiagen), and eluted in 10 μ l of EB buffer.

ATAC-seq data processing. Adaptor sequence trimming using SeqPurge and mapping to hg19 using Bowtie2 were performed. The reads were then filtered for mitochondrial reads, low-quality reads, and PCR duplicates. The filtered reads for each sample were merged, and peak calling was performed by MACS2. The reads in peaks for each individual sample were quantified using BEDTools intersect with the MACS2 narrow peaks. Peak counts were then combined into an $N \times M$ matrix where *N* represents called peaks, *M* represents the samples, and each value D_{ij} represents the peak intensity for respective peak *i* in sample *j*. This matrix was then normalized using the ‘CQN’ package in R to minimize bias in GC content and length.

CRISPRi validation of HiChIP targets. For virus production, 5×10^6 HEK293T cells were plated per 10-cm plate. The following day, plasmid encoding

lentivirus was cotransfected with pMD2.G and psPAX2 into the cells using Lipofectamine 3000 (Thermo Fisher, L3000) according to the manufacturer's instructions. Supernatant containing viral particles was collected 48 h after transfection and filtered. For lentivirus encoding individual sgRNAs, virus was concentrated tenfold using Lenti-X concentrator (Clontech, 631232) and stored at -80°C .

To generate a My-La cell line expressing CRISPRi, 2×10^6 My-La cells were plated per T75 flask. A dCas9-BFP-KRAB-2A-Blast construct was generated by inserting a 2A-Blast cassette into dCas9-BFP-KRAB (Addgene, 46911). 24 h after plating, lentivirus harboring the dCas9-KRAB construct was added with polybrene (4 $\mu\text{g}/\text{ml}$). The medium was changed 24 h after infection and then again 48 h after infection with blasticidin (Thermo Fisher, A1113903) at a 4 $\mu\text{g}/\text{ml}$ concentration. Blasticidin-resistant cells were selected for 8 d with the medium changed every other day.

Three different U6 sequences were used for transcription of three different sgRNAs targeting the candidate enhancers, as previously described⁵⁶. For the MYC locus CRISPRi experiments, each enhancer was targeted by one guide, and all MYC GM or My-La enhancers together were therefore targeted in one experiment. For the PICS SNP CRISPRi experiments, three guides were targeted to a single SNP-containing enhancer. One of three sgRNAs was cloned into a lentiviral vector with a human (pMJ117, Addgene, 85997), mouse (pMJ179, Addgene, 85996), or bovine (pMJ114, Addgene, 85995) U6 promoter. These U6-sgRNA constructs were then combined into a lentivirus with a Puromycin-2A-mCherry vector, which was modified from Addgene 46914. My-La-CRISPRi cells were infected with lentivirus harboring three sgRNAs and selected by puromycin (Thermo Fisher, A11138) at a final concentration of 1 $\mu\text{g}/\text{ml}$. Previously reported sgRNAs targeting VPS54 or SEC24C were used for validating CRISPRi functionality in the My-La cell line⁵⁷.

For readout of CRISPRi validation, we performed qRT-PCR and cell growth assays on three biological and two technical replicates. For qRT-PCR, RNA was extracted with TRIzol (Thermo Fisher, 15596026) and purified using the Zymo RNA Clean and Concentrator kit (Zymo Research, R1016). qRT-PCR was performed with Brilliant qRT-PCR Mastermix (Agilent, 600825). Ct values were measured using a LightCycler 480 instrument (Roche), and the relative expression level was calculated by the $\Delta\Delta\text{Ct}$ method in comparison to a GAPDH control. Primer sequences are listed in **Supplementary Table 6**. For cell growth, we used the CellTiter-Glo kit (Promega, G7572) according to the manufacturer's instructions. Statistics for both RNA and cell growth changes were calculated using a Student's *t* test against the non-targeting control.

CRISPRa validation of HiChIP targets. Jurkat cells were transduced with a lentiviral dCas9-VP64-2A-GFP expression vector (Addgene, 61422). Single GFP⁺ cells were sorted by FACS into the wells of a 96-well plate, and a clone with bright, uniform GFP expression were selected for use in future experiments.

sgRNAs were cloned in arrayed format for CD69 HiChIP peaks falling outside the range of the tiling CRISPRa screen²⁶. sgRNAs were chosen on the basis of high predicted on-target activity⁵⁸ and low predicted off-target

activity⁵⁹. sgRNAs were cloned into the lentiviral expression vector pCRISPRi-v2 (Addgene, 84832) as described in Horlbeck *et al.*⁶⁰. Lentivirus was produced by transfecting HEK293T cells with standard packaging vectors using TransIT-LTI Transfection Reagent (Mirus, MIR 2306). The medium was changed 24 h after transfection. Viral supernatant was harvested at 48 and 72 h following transfection and immediately used for infection of Jurkat-dCas9-VP64 cells.

Jurkat-dCas9-VP64 cells were infected with lentiviral sgRNAs by resuspending cells in a 1:1 mix of fresh medium and lentiviral supernatant at a final concentration of 0.25×10^6 cells/ml with 5 $\mu\text{g}/\text{ml}$ polybrene. Cells were spininfected for 1 h at 1,000 r.c.f. at 32°C . The next day, half of the medium was removed and replaced with fresh lentiviral supernatant and the spininfection was repeated. The next day, the cells were resuspended in fresh medium with 1.5 $\mu\text{g}/\text{ml}$ puromycin and cultured for 2 d to remove uninfected cells. For readout of CRISPRa validation, we performed qRT-PCR and FACS on two biological and two technical replicates. RNA extraction and qRT-PCR were performed as described above. Expression of CD69 on infected cells (GFP⁺BFP⁺) was analyzed by flow cytometry with an Attune NxT flow cytometer (Life Technologies). Statistics for both RNA- and protein-level changes were calculated with one-way ANOVA followed by a Dunnett's multiple-comparisons test against the non-targeting control.

Additional methods are provided in the **Supplementary Note**.

Data availability. Raw and processed data are available at the Gene Expression Omnibus (GEO) under accession [GSE101498](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101498). T cell ATAC-seq and HiChIP data sets can be visualized in the WashU Epigenome Browser with the following link: [98051079](https://epigenome.washu.edu/). A **Life Sciences Reporting Summary** is available.

50. Sinha, R. *et al.* Index switching causes "spreading-of-signal" among multiplexed samples in Illumina HiSeq 4000 DNA sequencing. Preprint at *bioRxiv* [http://dx.doi.org/10.1101/125724](https://doi.org/10.1101/125724) (2017).
51. Servant, N. *et al.* HiC-Pro: an optimized and flexible pipeline for Hi-C data processing. *Genome Biol.* **16**, 259 (2015).
52. Gjoneska, E. *et al.* Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease. *Nature* **518**, 365–369 (2015).
53. Kagey, M.H. *et al.* Mediator and cohesin connect gene expression and chromatin architecture. *Nature* **467**, 430–435 (2010).
54. Yue, F. *et al.* A comparative encyclopedia of DNA elements in the mouse genome. *Nature* **515**, 355–364 (2014).
55. Bonnal, R.J.P. *et al.* De novo transcriptome profiling of highly purified human lymphocytes primary cells. *Sci. Data* **2**, 150051 (2015).
56. Adamson, B. *et al.* A multiplexed single-cell CRISPR screening platform enables systematic dissection of the unfolded protein response. *Cell* **167**, 1867–1882 (2016).
57. Gilbert, L.A. *et al.* Genome-scale CRISPR-mediated control of gene repression and activation. *Cell* **159**, 647–661 (2014).
58. Doench, J.G. *et al.* Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. *Nat. Biotechnol.* **34**, 184–191 (2016).
59. Hsu, P.D. *et al.* DNA targeting specificity of RNA-guided Cas9 nucleases. *Nat. Biotechnol.* **31**, 827–832 (2013).
60. Horlbeck, M.A. *et al.* Nucleosomes impede Cas9 access to DNA *in vivo* and *in vitro*. *eLife* **5**, e12677 (2016).

Life Sciences Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.

For further information on the points included in this form, see [Reporting Life Sciences Research](#). For further information on Nature Research policies, including our [data availability policy](#), see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

▶ Experimental design

1. Sample size

Describe how sample size was determined.

Human donor sample sizes were chosen to provide sufficient confidence to validate methodological conclusions of the applicability of primary cell H3K27ac HiChIP.

Data exclusions

Describe any data exclusions.

None.

Replication

Describe whether the experimental findings were reliably reproduced.

All experiments were performed with two or three biological replicates and technical duplicates. The reproducibility analysis for H3K27ac HiChIP is presented in Supplementary Figures 2-4, and CRISPRi/a reproducibility is shown in the relevant sections of the main figures.

Randomization

Describe how samples/organisms/participants were allocated into experimental groups.

No randomization was used.

Blinding

Describe whether the investigators were blinded to group allocation during data collection and/or analysis.

No blinding was used.

Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.

Statistical parameters

For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).

- Confirmed
- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
 - A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
 - A statement indicating how many times each experiment was replicated
 - The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
 - A description of any assumptions or corrections, such as an adjustment for multiple comparisons
 - The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted
 - A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
 - Clearly defined error bars

See the web collection on [statistics for biologists](#) for further resources and guidance.

► Software

Policy information about [availability of computer code](#)

7. Software

Describe the software used to analyze the data in this study.

Where relevant, the software used for analysis is cited in the online methods (HiC-Pro, Juicebox, Juicer). All custom software is available upon request.

For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). *Nature Methods* [guidance for providing algorithms and software for publication](#) provides further information on this topic.

► Materials and reagents

Policy information about [availability of materials](#)

8. Materials availability

Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.

All materials other than donated biological material are available upon request.

9. Antibodies

Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).

Antibodies used for HiChIP included: H3K27ac (Abcam ab4729) and CTCF (Abcam ab70303). Antibodies used for FACS included: PerCP/Cy5.5 anti-CD45RA (Biolegend 304122), Brilliant Violet 510 anti-CD127 (Biolegend 351331), APC/Cy7 anti-CD4 (Biolegend 344616), PE anti-CCR6 (Biolegend 353410), FITC anti-CD25 (Biolegend 302603), Brilliant Violet 421 anti-CXCR3 (Biolegend 353715), and BB515 anti-CXCR5 (BD Biosciences 564625).

10. Eukaryotic cell lines

- State the source of each eukaryotic cell line used.
- Describe the method of cell line authentication used.
- Report whether the cell lines were tested for mycoplasma contamination.
- If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by [ICLAC](#), provide a scientific rationale for their use.

All cell lines in this study were purchased from ATCC.

All cell lines used in this study were purchased from ATCC. Where possible, cell lines were validated by comparison to published sequencing data or by in-house genotyping.

Cell lines were tested for mycoplasma contamination upon receipt and periodically thereafter but not prior to each experiment.

None.

Animals and human research participants

Policy information about [studies involving animals](#); when reporting animal research, follow the [ARRIVE guidelines](#)

11. Description of research animals

Provide details on animals and/or animal-derived materials used in the study.

None.

Policy information about [studies involving human research participants](#)

12. Description of human research participants

Describe the covariate-relevant population characteristics of the human research participants.

All patient samples were acquired from AllCells, and no identifying or health information was shared from normal healthy donors.